Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke

Dynamic Changes of Vascular Endothelial Growth Factor and Endostatin in Association With Circulating Endothelial Progenitor Cells After Acute Ischemic Stroke

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02157896

Enrollment

Registered

2014-06-06

Start date

2013-05-31

Completion date

2014-05-31

Last updated

2020-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Ischemic Stroke

Keywords

Acute ischemic stroke, Vascular endothelial growth factor, Endostatin

Brief summary

Vascular endothelial growth factor (VEGF) and Endostatin (ES) participate angiogenesis after cerebral ischemia. Circulating endothelial progenitor cells (EPCs) also play a crucial role in neovascularization and tissue repair after acute ischemic stroke (AIS). The investigators sought to compare the expression of VEGF and ES in serum and the circulating EPCs in patients after AIS with that of healthy control subjects. The investigators obtained peripheral blood and serum samples from study subjects. EPCs in blood samples from AIS patients and healthy controls were quantified by flow cytometry 1 day, 3 days, 5 days and 7 days after AIS. VEGF and ES were measured by enzyme linked immunosorbent assay at the same time points. The relation between them and the relation of them to prognosis of such patients with acute ischemic stroke were assessed.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to 74 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of acute ischemic stroke * Admission within 12 hours * National Institutes of Health Stroke Scale score 6-25

Exclusion criteria

* Lacunar infarction * Cerebral hemorrhagic infarction * Epilepsy or epileptic persons * History of neurological diseases, myocardial infarction, renal and hepatic abnormalities and metabolic diseases * Contraindications to antiplatelet treatments * Died within the first week of hospitalization * Serial blood samples could not be obtained

Design outcomes

Primary

Measure	Time frame	Description
Modified Rankin Scale scores	3 months	0 = No symptoms; 1 = No significant disability. Able to carry out all usual activities, despite some symptoms; 2 = Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 = Moderate \- Page 3 of 4 \[DRAFT\] - disability. Requires some help, but able to walk unassisted; 4 = Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 = Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 = Dead.

Secondary

Measure	Time frame	Description
Glasgow Outcome Scale scores	3 months	Glasgow Outcome Scale 1 = death; Glasgow Outcome Scale 2 = vegetative state; Glasgow Outcome Scale 3 = severe neurological deficit; Glasgow Outcome Scale 4 = mild neurological deficit and Glasgow Outcome Scale 5 = premorbid level of functioning or completely recovery.

Countries

China

Outcome results